DBV Technologies S.A. DBVT NASDAQ

DBV Technologies S.A. (DBVT) reported total assets of $233.72M and total liabilities of $64.95M for fiscal year 2025, resulting in total equity of $168.77M.

The company held $194.17M in cash and short-term investments. Total debt stood at $21.68M, with net debt of $-172.48M. The Debt-to-Equity (D/E) ratio was 0.13 (conservative).

Current ratio is 3.67, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0.13, current ratio of 3.67 — balance sheet is strong
• MOAT (21/100) — Total assets $233.72M and equity $168.77M support the company's competitive scale
• VALUE (100/100) — Debt-to-Equity 0.13 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 55/100 with 3/7 criteria passed.

NUVL

Nuvalent, Inc.

$104.75

-0.26%

CELC

Celcuity Inc.

$123.47

+2.17%

CNTA

Centessa Pharmaceuticals plc

$39.61

+0.05%

OPT

Opthea Limited

$3.41

+1.49%

EWTX

Edgewise Therapeutics, Inc.

$33.70

+1.63%

TARS

Tarsus Pharmaceuticals, Inc.

$71.80

-2.72%

PNT

POINT Biopharma Global Inc.

$12.50

+0.16%

INBX

Inhibrx Biosciences, Inc.

$83.60

+0.49%